DRDO invites EOIs for technology delivery of 2-DG drug

Hyderabad, June 9 (PTI) The Defense Research and Development Organization (DRDO), which has developed 2-deoxy-D-glucose (2-DG), a drug used in the treatment of Kovid-19 patients, has developed the technology to make this drug in India. Expression of Interest (EoI) has been invited for transfer to the pharmaceutical industry.

The 2-DG drug has been developed by DRDO’s laboratory, Institute of Nuclear Medicine and Allied Sciences (INMAS) in association with Dr. Reddy Laboratories.

Clinical trial results showed that this molecule helps hospitalized patients recover faster and reduce their dependence on oxygen.

As per the EOI document, applications should be sent through email before June 17. “The EoIs to be given by the industries will be examined by a Technical Assessment Committee (TAC). Only 15 industries will be given ToT on the basis of their capabilities and first come first serve basis.

The bidders should have license to manufacture drugs from active pharmaceutical ingredients (APIs) from drug licensing authorities.

.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *